{"id":"NCT01569464","sponsor":"UCB Pharma","briefTitle":"Rotigotine Effect on All-day Functioning and Quality of Life in Subjects With Moderate to Severe Restless Legs Syndrome (RLS)","officialTitle":"A Phase 3B, Double-Blind, Randomized, Placebo-Controlled Study of Rotigotine and Its Effect on All-Day Functioning and Quality of Life in Subjects With Moderate to Severe Idiopathic Restless Legs Syndrome","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-03","primaryCompletion":"2013-04","completion":"2013-04","firstPosted":"2012-04-03","resultsPosted":"2014-08-26","lastUpdate":"2014-08-26"},"enrollment":150,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Restless Legs Syndrome"],"interventions":[{"type":"DRUG","name":"Rotigotine","otherNames":["NeuproÂ®"]},{"type":"OTHER","name":"Placebo","otherNames":[]}],"arms":[{"label":"Rotigotine","type":"ACTIVE_COMPARATOR"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of the study is to show that Rotigotine improves Restless Legs Syndrome (RLS) symptoms in subjects with moderate to severe RLS during both day and evening.","primaryOutcome":{"measure":"Change From Baseline To The End Of The Maintenance Period in International Restless Legs Scale (IRLS) Sum Score","timeFrame":"Baseline to End of Maintenance Period (approximately 7 weeks)","effectByArm":[{"arm":"Rotigotine","deltaMin":-15.46,"sd":1},{"arm":"Placebo","deltaMin":-15.19,"sd":1.29}],"pValues":[{"comp":"OG000 vs OG001","p":"0.8451"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":16,"exclusionCount":23},"locations":{"siteCount":18,"countries":["United States"]},"refs":{"pmids":["26569149"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":101},"commonTop":["Nausea","Headache","Application site pruritus","Somnolence","Dizziness"]}}